news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

On July 30, Shanghai issued the "Several Opinions on Supporting the Innovation and Development of the Whole Chain of the Biopharmaceutical Industry", which proposed to accelerate the innovation of basic theories and breakthroughs in cutting-edge technologies. It also called for the promotion of the new model of contract research and production organizations (CMOs), and aimed at basic cutting-edge fields and new tracks such as cell and gene therapy, mRNA, synthetic biology, and regenerative medicine by leveraging the role of innovation platforms such as national strategic scientific and technological forces.

At present, Shanghai has built a CRO/CMO technology service industry cluster represented by Boehringer Ingelheim and other companies, and has established a public service platform system covering all factors and chains, from target discovery to registration and listing, and commissioned production. These platforms are providing full-chain, high-quality and efficient professional services for innovative drugs, speeding up the development of new drugs. For example, Boehringer Ingelheim has signed a commissioned production agreement with BeiGene to produce its PD-1 inhibitor tislelizumab (Beizer) in Shanghai.

In recent years, Chinese pharmaceutical companies have actively explored the path of international development, and their international competitiveness and global contribution have continued to increase. Global cooperation in innovative drugs has become an important direction for the development of my country's biopharmaceuticals.

As Shanghai continues to promote the development of innovative biopharmaceuticals, more and more multinational companies are planning to increase their investment. Yicai Global learned from Wacker Chemical that the company is evaluating the development of pharmaceutical services in China. Wacker provides a range of services in the field of biotechnology, including analysis and process development, as well as the production of clinical and commercial biological preparations in accordance with GMP standards.

At the "Innovative Biological Drug Cooperation and Development Seminar" co-organized by Wacker Chemie and Shanghai Biomedical Technology Development Center on July 30, Guido Seidel, Global Vice President of Wacker Biotech, shared the global market dynamics of mRNA drugs. He said: "As the global biopharmaceutical market recovers, Wacker can provide one-stop services to pharmaceutical companies with its global production network and unique flexibility."

It is understood that the seminar also specifically discussed topics such as protein drug and mRNA drug innovation, as well as the regulatory system and policy of biopharmaceutical sample import and export regulations, overseas CDMO cooperation and investment and financing. Guido Seidel said: "Whether in terms of investment or the number of clinical trials, the global biopharmaceutical market has shown signs of recovery, and the development of new drugs may accelerate. This trend will bring more market opportunities to Wacker."

In June this year, Wacker announced that its mRNA technology center was officially put into use at its biotechnology production base in Halle, Germany. With the opening of this technology center, Wacker will be able to mass-produce mRNA active ingredients in the future. In May this year, Wacker Biotech (USA) Inc., a wholly-owned subsidiary of Wacker Chemicals, also announced the expansion of its mRNA and protein production scale.

However, industry insiders told the First Financial reporter that given the characteristics of this new technology, mRNA, it is necessary to break through existing regulatory rules within an appropriate scope, including existing drug registration and clinical trial management, production processes, etc. This is one of the main obstacles for related products to obtain approval.